The One Big Beautiful Bill Act (OBBA), which extended and enhanced the 2017 Tax Cuts and Jobs Act, included other significant benefits to taxpayers, including the termination of a disastrous software program at the Internal Revenue Service (IRS). Citizens Against Government Waste raised the alarm for many years over the idea of allowing the IRS […]
The Federal Trade Commission (FTC) should review and reconsider the ongoing cases that began during the Biden administration under Chair Lina Khan. Her approach to antitrust law, along with her anti-capitalist and anti-business policies led to her being named Citizens Against Government Waste’s September 2023 and November 2024 Porker of the Month. The legal quagmire […]
The debate over raising the federally insured deposit limit has been heating up following the failure of Silicon Valley Bank and Signature Bank, even though doing so would increase risk and moral hazard, and the banks’ demise was unrelated to the insurance cap. The Federal Reserve’s April 28, 2023, review of its supervision of Silicon […]
Following the Biden administration’s multi-trillion spending spree, which has pushed the national debt to $36.9 trillion, the government must tighten its belt and cut costs. After the House passed the One Big Beautiful Bill Act and it moved to the Senate, President Trump took the next step in his efforts to cut waste, fraud, and […]
Welcome to This Week in Waste, a series by Citizens Against Government Waste (CAGW) that highlights how taxpayer dollars are being wasted in the federal, state, and local levels of government, and efforts to fight back against this spendthrift behavior. President Trump’s Budget Proposal Cuts Hundreds of Billions in Spending President Trump sent his […]
The Trump administration has been moving headlong into reducing the regulatory burden on industries that are trying to invest and build in America. After President Trump released two Executive Orders (EO) on eliminating regulations, federal agencies are taking note and moving forward. Congress is also considering legislation to increase its role in reviewing regulations. Federal […]
Prices controls have always disrupted the marketplace and created shortages or excesses.
Price controls will result in the loss of life due to a lack of future research and development.
Price controls on pharmaceuticals will not lower prices and will lead to fewer future cures.
President Biden’s support of intellectual property waivers threatens development of future life-saving medicines.
